Healthcare, Pharma & Life Sciences

CelluPro Becomes First Chinese Firm With EXCiPACT GMP Certification

Yantai, China – September 10, 2026 -- CelluPro has secured EXCiPACTTM GMP certification for pharmaceutical auxiliary materials, becoming the first Chinese cell culture media supplier to receive the internationally recognized credential.

EXCiPACT certification validates GMP compliance for biopharma raw materials

The EXCiPACTTM program sets GMP requirements for materials used in biopharmaceutical manufacturing, assessing quality management, manufacturing controls, traceability and supply chain practices. For cell culture media suppliers, the certification serves as an internationally recognized benchmark for GMP-compliant production and quality management.

NGO Warns AfD's Saxony-Anhalt Win Threatens Healthcare Access

Munich – – September 10, 2026 -- Medical relief organization Ärzte der Welt has warned that the AfD's election victory in Saxony-Anhalt could jeopardize healthcare access for vulnerable populations across Germany, citing risks to uninsured patients, refugee families and homeless individuals.

AfD's potential Bundesrat entry raises funding risks for uninsured care

Ärzte der Welt Director Katri Bertram said that if the AfD takes over the state government and enters the Bundesrat, it could endanger patient health in Magdeburg and nationwide. She specifically flagged risks to families fleeing war zones, homeless people and those in poverty, warning that increased exclusion could worsen population-wide health outcomes, including unchecked infectious diseases.

Nutromics Names DNA-Sensor Inventor Plaxco as Chief Scientific Officer

Image
Nutromics Names DNA-Sensor Inventor Plaxco as Chief Scientific Officer

Melbourne – – September 10, 2026 -- Nutromics, a Melbourne-based wearable diagnostics startup, has appointed Professor Kevin W. Plaxco, the inventor of its core DNA-based sensing technology, as Chief Scientific Officer ahead of its first product launch planned for 2027.

Plaxco takes over as CSO from Justin Gooding, who remains on the Biosensor Advisory Board

Professor Plaxco succeeds Scientia Professor Justin Gooding in the role. Gooding will continue to serve on Nutromics' Biosensor Advisory Board, a group Plaxco previously chaired as an advisor since the company licensed his technology from co-founders Peter Vranes and Hitesh Mehta.

Rznomics Boosts Circular RNA Yield 7-Fold, Beats PIE Method 2x

Image
Rznomics Boosts Circular RNA Yield 7-Fold, Beats PIE Method 2x

Seongnam, South Korea – September 10, 2026 -- Rznomics Inc. (KOSDAQ: 476830) has achieved up to a seven-fold increase in circular RNA (circRNA) production efficiency through engineering upgrades to its proprietary Self-Targeting and Splicing (STS) platform, according to peer-reviewed research published in Nucleic Acids Research on September 10, 2026.

Optimized STS method doubles circularization efficiency versus industry-standard PIE technique

In tests using Factor VIII RNA measuring approximately 7.8 kilo-nucleotides in length, the upgraded STS approach delivered roughly twice the circularization efficiency of the widely used Permuted Intron–Exon (PIE) method, a standard benchmark in circRNA manufacturing. The finding directly addresses a persistent industry constraint: circularization efficiency typically drops as RNA length increases, limiting the size of genes that can be produced at commercial scale.

Aroa's Myriad Scaffold Shows 0.7% Deep Infection Rate in 411-Patient Study

Image
Aroa's Myriad Scaffold Shows 0.7% Deep Infection Rate in 411-Patient Study

Auckland – September 10, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that interim results from its MASTRR Registry found deep tissue infection in just 0.7% of patients treated with its Myriad Matrix and Myriad Morcells bioscaffolds, with no adverse events causally linked to the products.

Largest published prospective bioscaffold study covers 411 patients, 474 defects

The peer-reviewed analysis, published in Advances in Therapy, tracked 411 patients and 474 soft tissue defects across 10 US centers. Aroa says this represents, to its knowledge, the largest published prospective analysis of a bioscaffold in in-patient soft tissue reconstruction.

Harbour BioMed Joins Stock Connect After Seven Profitable Half-Years

Image
Harbour BioMed Joins Stock Connect After Seven Profitable Half-Years

Shanghai – September 10, 2026 -- Harbour BioMed (HKEX: 02142.HK) shares became eligible for trading under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening direct access for qualified mainland Chinese investors effective immediately.

Market capitalization crosses HK$10 billion threshold

The inclusion follows the Company's market capitalization steadily surpassing HK$10 billion, placing it among large- and mid-cap biopharmaceutical issuers on the Hong Kong exchange.

First-half 2026 revenue rises 20.9% to $122.5 million

Harbour BioMed recorded total revenue of approximately US$122.5 million in the first half of 2026, up 20.9% year-over-year. Adjusted net profit reached approximately US$71.6 million, marking seven consecutive profitable half-years. Cash and cash equivalents stood at approximately US$359.2 million as of September 10, 2026.

Clover's RSV+hMPV±PIV3 Vaccine Hits Phase 2 Goals in Older Adults

Shanghai – September 10, 2026 -- Clover Biopharmaceuticals (HKEX: 02197) reported positive preliminary Phase 2 data in Australia for two combination respiratory vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), targeting older adults aged 60-85.

Trial enrolled 420 older adults across multiple Australian sites

The randomized, observer-blinded study randomized 420 participants to receive SCB-1022, SCB-1033 or placebo. Antibody titers at 28 days post-vaccination were in line with or trended higher than prior Phase 1 results.

DKOU 2026 Opens Registration, Targets Orthopedic Workforce Gap

Image
DKOU 2026 Opens Registration, Targets Orthopedic Workforce Gap

Berlin – September 10, 2026 -- The German Congress for Orthopaedics and Trauma Surgery (DKOU) 2026 has published its full program and opened registration, with the four-day event set to run October 20-23, 2026 at CityCube Berlin.

DGOOC president frames congress as a hub for continuing education amid staff shortages

In a video interview released as part of a three-part series under the motto "Neue Wege gehen" (Taking New Paths), Dr. Jörn Dohle, president of the German Society for Orthopaedics and Orthopaedic Surgery (DGOOC), described DKOU as a "market of possibilities" combining specialized clinical content, interdisciplinary exchange and cross-sector dialogue. Dohle pointed to workforce shortages as a central challenge for the field, noting that while digital tools can support parts of patient care, recruiting young physicians and providing structured learning and exchange formats remains critical.

CelluPro Becomes First China Firm to Win EXCiPACT GMP Certification

Yantai – September 10, 2026 -- CelluPro has become the first Chinese cell culture media supplier to receive EXCiPACTTM GMP Certification for Pharmaceutical Auxiliary Materials, adding an internationally recognized quality benchmark to its biomanufacturing supply chain.

EXCiPACT Certification Validates Manufacturing Controls and Traceability

The EXCiPACTTM scheme sets GMP requirements for materials used in biopharmaceutical manufacturing, assessing quality management, manufacturing controls, traceability, and supply chain practices. CelluPro's certification adds to an existing compliance portfolio that includes ISO 9001, ISO 13485, ISO 14001, ISO 45001, and ISO 22301, covering quality management, environmental management, occupational health and safety, and business continuity.

Sky Labs' CART Ring Hits 300,000 Prescriptions, Enters Korea BP Guidelines

Image
Sky Labs' CART Ring Hits 300,000 Prescriptions, Enters Korea BP Guidelines

Munich – September 10, 2026 -- Sky Labs presented new clinical data at ESC Congress 2026 showing its ring-shaped blood pressure monitor, CART, achieves an approximately 80% data-usability rate in continuous 24-hour monitoring of patients with atrial fibrillation, addressing a measurement gap left by traditional cuff-based devices in patients with irregular pulse or severe blood pressure fluctuations.

Chonnam University trial confirms 24-hour monitoring feasibility in atrial fibrillation patients

Professor Ki-Hong Lee of Chonnam National University Hospital reported that CART enabled precise observation of nocturnal blood pressure dipping patterns in atrial fibrillation patients, with a data-usability rate near 80% across continuous 24-hour recordings.